Holly Bryan
Internal Medicine · Clairton, PANPI 1073294328
Payments from drug & device makers
Across 128 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$535
- Exact Sciences$290
- Pfizer$222
- Currax Pharmaceuticals LLC$214
- Amgen$179
- GSK$141
- plus $703 from 19 others
What the payments were for
- Food & beverage$2,283100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 29 | $535 |
| Exact Sciences | 17 | $290 |
| Pfizer | 12 | $222 |
| Currax Pharmaceuticals LLC | 14 | $214 |
| Amgen | 12 | $179 |
| GSK | 8 | $141 |
| Abbott | 6 | $108 |
| AbbVie | 4 | $83 |
| Lilly USA, LLC | 4 | $76 |
| Lundbeck LLC | 3 | $58 |
| Boston Scientific | 2 | $50 |
| AstraZeneca(2 entities) | 3 | $48 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Abiomed | 1 | $31 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $28 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Edwards Lifesciences | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
| Merck | 1 | $21 |
| Ardelyx, Inc. | 1 | $17 |
| Bayer | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Si-bone, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $13 |
| Phadia US Inc. | 1 | $13 |
How this compares
$2,283 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $11,010 |
| MyrbetriqMirabegron | 12 | $8,750 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,669 |
| Levothyroxine Sodium | 81 | $1,574 |
| Vilazodone Hcl | 13 | $1,249 |
| Potassium Chloride | 42 | $1,214 |
| Solifenacin Succinate | 29 | $700 |
| Pantoprazole Sodium | 83 | $689 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $496 |
| SynthroidLevothyroxine Sodium | 18 | $388 |
| Atorvastatin Calcium | 51 | $379 |
| Prednisone | 162 | $299 |
| NitrofurantoinNitrofurantoin Macrocrystal | 32 | $270 |
| Lisinopril | 40 | $242 |
| Montelukast Sodium | 15 | $240 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $222 | $11,01012 claims |
| Astellas Pharma US IncMyrbetriq | $21 | $8,75012 claims |
| GSKTrelegy Ellipta | $141 | $7,66912 claims |
| AbbVieSynthroid | $83 | $38818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Clairton
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Christopher StillDanville$7.1M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
- Michael OliverBeaver$4.7M
- Raman PurighallaPittsburgh$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.